In his only season as a Longhorn, Johnson averaged 19.9 points per game while shooting 39.7 from three-point range. As the Longhorns struggled to string wins together, Johnson was arguably their best player. That was partly why he was one of the most talked about prospects heading into the draft.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the largest and most well-known pharmaceutical companies in the world.

DC fans have hilariously thanked former “Black Adam” actor Dwayne Johnson for James Gunn’s “Superman” success, which opened nationally in theaters Friday and raked in the year’s best box office preview total with $22.5 million.

Writer-director Rian Johnson talks about the 'Poker Face' Season 2 ending, working with Natasha Lyonne, his next 'Knives Out' movie, and Star Wars.

The Washington Wizards faced the Phoenix Suns on Friday at the 2K26 Summer League with a fully NBA-rostered starting five: Bub Carrington, Tre Johnson, Kyshawn

With Isaiah Jackson's re-signing the Pacers now have 15 players on standard contracts. Thomas Bryant and James Johnson Jr. are not among them.

Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

Two years after posting his last LIV Golf win at Andalucía, Talor Gooch is displaying the same kind of form that won him the league’s solo title.

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter,